{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T06:04:46Z","timestamp":1780639486685,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Inflamm"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Inflammation can be an unwanted consequence or cause of debilitating diseases of infectious and non-infectious aetiologies. Current anti-inflammatory medications have several deficiencies including lack of specificity and undesirable side effects. Herein, the potential of non-ionic surfactant vesicles (NISV) comprised of monopalmityol glycerol, dicetyl phosphate and cholesterol) as an anti-inflammatory drug and their mode of action is investigated. NISV were able to inhibit LPS-induced IL-6 from BMD macrophages. The individual components of NISV, monopalmityol glycerol, dicetyl phosphate and cholesterol did not affect LPS induced IL-6 levels, proving that formulation of NISV is essential for their anti-inflammatory effects. Transcriptomic analyses showed NISV mediated down-regulation of transcripts for inflammatory mediators in LPS stimulated macrophages. Notably, NISV downregulate NF-\u03baB transcripts in LPS stimulated macrophages. Measurement of inflammatory mediators by cytometric bead array validated a number of transcriptomic findings as NISV were found to inhibit LPS induced IL-6, IL-12, and multiple chemokines. Further investigation demonstrated that NISV inhibited Poly(I:C) or Pam3csk4 induced inflammatory mediators. This indicates that the effects of NISV are distal to both MyD88 and TRIF signalling. Overall, the data generated highlights the potential of NISV as an anti-inflammatory therapeutic.<\/jats:p>","DOI":"10.1186\/s12950-024-00419-5","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T11:33:55Z","timestamp":1732620835000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-ionic surfactant vesicles exert anti-inflammatory effects through inhibition of NF\u03baB"],"prefix":"10.1186","volume":"21","author":[{"given":"Jonathan","family":"McGahon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Woods","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"D\u2019Elia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"419_CR1","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1017\/S1462399411001943","volume":"13","author":"TJ Koh","year":"2011","unstructured":"Koh TJ, DiPietro LA. Inflammation and wound healing: the role of the macrophage. Expert Rev Mol Med. 2011;13:e23.","journal-title":"Expert Rev Mol Med"},{"issue":"7203","key":"419_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nature07201","volume":"454","author":"R Medzhitov","year":"2008","unstructured":"Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454(7203):428\u201335.","journal-title":"Nature"},{"key":"419_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mib.2013.11.004","volume":"17","author":"M Otto","year":"2014","unstructured":"Otto M. Staphylococcus aureus toxins. Curr Opin Microbiol. 2014;17:32\u20137.","journal-title":"Curr Opin Microbiol"},{"issue":"5","key":"419_CR4","doi-asserted-by":"publisher","first-page":"e1002022","DOI":"10.1371\/journal.pmed.1002022","volume":"13","author":"JL Vincent","year":"2016","unstructured":"Vincent JL. The clinical challenge of sepsis identification and monitoring. PLoS Med. 2016;13(5):e1002022.","journal-title":"PLoS Med"},{"issue":"1","key":"419_CR5","doi-asserted-by":"publisher","first-page":"010404","DOI":"10.7189\/jogh.01.010404","volume":"2","author":"I Jawad","year":"2012","unstructured":"Jawad I, Luksic I, Rafnsson SB. Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health. 2012;2(1):010404.","journal-title":"J Glob Health"},{"key":"419_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.602848","volume":"12","author":"CO Olwal","year":"2021","unstructured":"Olwal CO, et al. Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19. Front Immunol. 2021;12: 602848.","journal-title":"Front Immunol"},{"issue":"1\u20133","key":"419_CR7","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejphar.2005.12.052","volume":"533","author":"PJ Barnes","year":"2006","unstructured":"Barnes PJ. Corticosteroids: the drugs to beat. Eur J Pharmacol. 2006;533(1\u20133):2\u201314.","journal-title":"Eur J Pharmacol"},{"key":"419_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3389\/fphar.2017.00460","volume":"8","author":"P Li","year":"2017","unstructured":"Li P, Zheng Y, Chen X. Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics. Front Pharmacol. 2017;8:460.","journal-title":"Front Pharmacol"},{"key":"419_CR9","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.","journal-title":"BMJ"},{"key":"419_CR10","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.015","volume":"185","author":"S Moghassemi","year":"2014","unstructured":"Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185:22\u201336.","journal-title":"J Control Release"},{"issue":"1","key":"419_CR11","first-page":"1","volume":"1","author":"A Pardakhty","year":"2013","unstructured":"Pardakhty A, Moazeni E. Nano-niosomes in drug, vaccine and gene delivery: a rapid overview. Nanomed J. 2013;1(1):1\u201312.","journal-title":"Nanomed J"},{"key":"419_CR12","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jconrel.2020.05.048","volume":"324","author":"S Woods","year":"2020","unstructured":"Woods S, et al. Glucosamine-NISV delivers antibody across the blood-brain barrier: optimization for treatment of encephalitic viruses. J Control Release. 2020;324:644\u201356.","journal-title":"J Control Release"},{"issue":"20\u201322","key":"419_CR13","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1016\/S0264-410X(00)00537-5","volume":"19","author":"M Conacher","year":"2001","unstructured":"Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001;19(20\u201322):2965\u201374.","journal-title":"Vaccine"},{"key":"419_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jconrel.2019.02.002","volume":"298","author":"RV D'Elia","year":"2019","unstructured":"D\u2019Elia RV, et al. Exploitation of the bilosome platform technology to formulate antibiotics and enhance efficacy of melioidosis treatments. J Control Release. 2019;298:202\u201312.","journal-title":"J Control Release"},{"issue":"4","key":"419_CR15","first-page":"570","volume":"75","author":"JM Brewer","year":"1992","unstructured":"Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB\/c humoral response to bovine serum albumin. Immunology. 1992;75(4):570\u20135.","journal-title":"Immunology"},{"key":"419_CR16","unstructured":"Roberts CW, Brewer JM, Alexander J. Non-ionic surfactant vesicles as therapeutic agent (Worldwide Patent No WO1997004768A1). World Intellectual Property Organization; 1997."},{"issue":"2","key":"419_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1128\/JCM.43.2.629-634.2005","volume":"43","author":"J McBride","year":"2005","unstructured":"McBride J, et al. Development of colorimetric microtiter plate assay for assessment of antimicrobials against Acanthamoeba. J Clin Microbiol. 2005;43(2):629\u201334.","journal-title":"J Clin Microbiol"},{"issue":"5","key":"419_CR18","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell C, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28(5):511\u20135.","journal-title":"Nat Biotechnol"},{"issue":"24","key":"419_CR19","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1093\/bioinformatics\/btx499","volume":"33","author":"Y Gloaguen","year":"2017","unstructured":"Gloaguen Y, et al. PiMP my metabolome: an integrated, web-based tool for LC-MS metabolomics data. Bioinformatics. 2017;33(24):4007\u20139.","journal-title":"Bioinformatics"},{"issue":"4","key":"419_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/bios14040156","volume":"14","author":"J Petiti","year":"2024","unstructured":"Petiti J, Revel L, Divieto C. Standard operating procedure to optimize resazurin-based viability assays. Biosensors. 2024;14(4):156.","journal-title":"Biosensors"},{"issue":"5","key":"419_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1136\/gut.2006.103564","volume":"56","author":"G D'Haens","year":"2007","unstructured":"D\u2019Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut. 2007;56(5):725\u201332.","journal-title":"Gut"},{"key":"419_CR22","unstructured":"Williamson ED, D'ELIA RV, Roberts CW, Woods S. Methods for the preparation of a pharmaceutical-vesicle formulation and associated products and uses. (Worldwide Patent No WO2020053541A1). World Intellectual Property Organization; 2020."},{"issue":"23","key":"419_CR23","doi-asserted-by":"publisher","first-page":"21763","DOI":"10.1074\/jbc.M501759200","volume":"280","author":"Y Li","year":"2005","unstructured":"Li Y, et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappaB- and map kinase-dependent inflammation in advanced atherosclerosis. J Biol Chem. 2005;280(23):21763\u201372.","journal-title":"J Biol Chem"},{"key":"419_CR24","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.3389\/fimmu.2019.01462","volume":"10","author":"A Viola","year":"2019","unstructured":"Viola A, et al. The metabolic signature of macrophage responses. Front Immunol. 2019;10:1462.","journal-title":"Front Immunol."},{"issue":"7","key":"419_CR25","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/cr.2015.68","volume":"25","author":"B Kelly","year":"2015","unstructured":"Kelly B, O\u2019Neill LAJ. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. Cell Res. 2015;25(7):771\u201384.","journal-title":"Cell Res"},{"issue":"7","key":"419_CR26","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s42255-019-0083-2","volume":"1","author":"GL Seim","year":"2019","unstructured":"Seim GL, et al. Two-stage metabolic remodelling in macrophages in response to lipopolysaccharide and interferon-\u03b3 stimulation. Nat Metab. 2019;1(7):731\u201342.","journal-title":"Nat Metab"},{"issue":"5","key":"419_CR27","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41577-019-0128-5","volume":"19","author":"LAJ O'Neill","year":"2019","unstructured":"O\u2019Neill LAJ, Artyomov MN. Itaconate: the poster child of metabolic reprogramming in macrophage function. Nat Rev Immunol. 2019;19(5):273\u201381.","journal-title":"Nat Rev Immunol"},{"issue":"7444","key":"419_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nature11986","volume":"496","author":"GM Tannahill","year":"2013","unstructured":"Tannahill GM, et al. Succinate is an inflammatory signal that induces IL-1\u03b2 through HIF-1\u03b1. Nature. 2013;496(7444):238\u201342.","journal-title":"Nature"},{"issue":"5243","key":"419_CR29","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1126\/science.270.5243.1811","volume":"270","author":"F Cocchi","year":"1995","unstructured":"Cocchi F, et al. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270(5243):1811\u20135.","journal-title":"Science"},{"issue":"5","key":"419_CR30","doi-asserted-by":"publisher","first-page":"H1976","DOI":"10.1152\/ajpheart.00153.2005","volume":"289","author":"DF Smith","year":"2005","unstructured":"Smith DF, et al. GRO family chemokines are specialized for monocyte arrest from flow. Am J Physiol Heart Circ Physiol. 2005;289(5):H1976\u201384.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"419_CR31","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1128\/JVI.78.4.1665-1674.2004","volume":"78","author":"T Nakayama","year":"2004","unstructured":"Nakayama T, et al. Selective induction of Th2-attracting chemokines CCL17 and CCL22 in human B cells by latent membrane protein 1 of Epstein-Barr virus. J Virol. 2004;78(4):1665\u201374.","journal-title":"J Virol"},{"issue":"7","key":"419_CR32","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1084\/jem.185.7.1163","volume":"185","author":"VP Patel","year":"1997","unstructured":"Patel VP, et al. Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J Exp Med. 1997;185(7):1163\u201372.","journal-title":"J Exp Med"},{"issue":"4","key":"419_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/intimm\/dxq005","volume":"22","author":"H Tsukamoto","year":"2010","unstructured":"Tsukamoto H, et al. Lipopolysaccharide-binding protein-mediated Toll-like receptor 4 dimerization enables rapid signal transduction against lipopolysaccharide stimulation on membrane-associated CD14-expressing cells. Int Immunol. 2010;22(4):271\u201380.","journal-title":"Int Immunol"},{"issue":"4975","key":"419_CR34","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1126\/science.1698311","volume":"249","author":"SD Wright","year":"1990","unstructured":"Wright SD, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science. 1990;249(4975):1431\u20133.","journal-title":"Science"},{"key":"419_CR35","doi-asserted-by":"publisher","first-page":"32","DOI":"10.3389\/fcimb.2013.00032","volume":"3","author":"I Zanoni","year":"2013","unstructured":"Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. Front Cell Infect Microbiol. 2013;3:32.","journal-title":"Front Cell Infect Microbiol"},{"issue":"49","key":"419_CR36","doi-asserted-by":"publisher","first-page":"6842","DOI":"10.1038\/sj.onc.1203237","volume":"18","author":"TD Gilmore","year":"1999","unstructured":"Gilmore TD. The Rel\/NF-kappaB signal transduction pathway: introduction. Oncogene. 1999;18(49):6842\u20134.","journal-title":"Oncogene"},{"issue":"1","key":"419_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrm2083","volume":"8","author":"ND Perkins","year":"2007","unstructured":"Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2007;8(1):49\u201362.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"419_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1021\/acscentsci.2c01351","volume":"9","author":"JY Kim","year":"2023","unstructured":"Kim JY, et al. Discovery of new states of immunomodulation for vaccine adjuvants via high throughput screening: expanding innate responses to PRRs. ACS Cent Sci. 2023;9(3):427\u201339.","journal-title":"ACS Cent Sci"}],"container-title":["Journal of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12950-024-00419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12950-024-00419-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12950-024-00419-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:04:38Z","timestamp":1732622678000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal-inflammation.biomedcentral.com\/articles\/10.1186\/s12950-024-00419-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["419"],"URL":"https:\/\/doi.org\/10.1186\/s12950-024-00419-5","relation":{},"ISSN":["1476-9255"],"issn-type":[{"value":"1476-9255","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"9 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}